Concurrent therapy with immune checkpoint inhibitors and TNF α blockade in patients with gastrointestinal immune-related adverse events
ConclusionsConcurrent treatment with anti-TNF α and ICI appears to be safe, facilitates steroid tapering, and prevents irEC. Prospective clinical trials are needed to assess the outcomes of this treatment modality.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Endoscopy | Gastroenterology | Immunotherapy | Lower Endoscopy | Remicade | Steroid Therapy | Study | Upper Endoscopy | Yervoy